Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

SNDXBearishIndustry Newsnews

High materiality8/10

Syndax Stock Drops After Phase 2 IPF Trial Misses Primary Endpoint

Oct 13, 2026, 8:25 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Immediate 17% premarket drop indicates likely near-term valuation pressure on SNDX; failed Phase 2 endpoint raises concern about axatilimab’s commercial potential and may trigger revisions to capital plans or strategic options, similar to past biotech setbacks where post-data discounts persisted for weeks.

AI summary

What happened, with direct paths to the underlying reporting

Syndax (SNDX) saw a sharp premarket drop after MAXPIRE Phase 2 data showed axatilimab failed to meet the primary endpoint in idiopathic pulmonary fibrosis, specifically the annualized rate of decline in forced vital capacity. The setback casts doubt on the program’s near-term value and could influence Syndax’s financing options and potential partnering discussions in the coming months.

SNDX fell 17.2% premarket after MAXPIRE Phase 2 failed.
Primary endpoint: annualized rate of decline in FVC not met.
Share price around $13.70 premarket.
Axatilimab pipeline and Syndax's funding needs under scrutiny.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.